Torrent Pharmaceuticals has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported significant growth, with total quarterly revenue reaching Rs 4,197 crore, a 42% increase year-over-year. For the full financial year 2025-26, total revenue climbed to Rs 13,980 crore, reflecting a solid 21% growth driven by strong performances across its key markets, including India, the United States, and Brazil.
Quarterly Performance Review (Q4 FY26)
The fourth quarter of the 2025-26 fiscal year (January-March) demonstrated exceptional momentum. Total revenue for the quarter stood at Rs 4,197 crore, compared to Rs 2,959 crore in the same quarter last year, marking a robust growth of 42%. The Indian market remains the primary revenue driver, contributing Rs 2,215 crore with a growth rate of 43%. Additionally, the ‘Others’ segment saw a substantial increase, rising by 68% to reach Rs 798 crore.
Annual Financial Results (FY 26)
For the full fiscal year ended March 31, 2026, Torrent Pharmaceuticals achieved a total revenue of Rs 13,980 crore, compared to Rs 11,516 crore in the previous year, representing a healthy 21% year-on-year growth. India continues to be the largest market with annual revenues of Rs 7,645 crore, growing by 20%. Both the United States and Brazil demonstrated consistent expansion, each reporting 24% growth and reaching Rs 1,363 crore and Rs 1,362 crore respectively.
Strategic Market Insights
The consistent double-digit growth across all major geographies highlights the company’s strong operational execution. The 32% growth in the ‘Others’ segment and a steady 10% growth in Germany further emphasize the company’s diversified and growing global footprint as it concludes the FY26 period.
Source: BSE
